View source for 20240041919. TOPICALLY ADMINISTERED STRONTIUM-CONTAINING COMPLEXES FOR TREATING PAIN, PRURITIS AND INFLAMMATION simplified abstract (Galleon Labs LLC)

=TOPICALLY ADMINISTERED STRONTIUM-CONTAINING COMPLEXES FOR TREATING PAIN, PRURITIS AND INFLAMMATION=


==Organization Name==

[[:Category:Galleon Labs LLC|Galleon Labs LLC]]


[[Category:Galleon Labs LLC]]

==Inventor(s)==

[[:Category:Gary S. Hahn of San Diego CA (US)|Gary S. Hahn of San Diego CA (US)]][[Category:Gary S. Hahn of San Diego CA (US)]]

==TOPICALLY ADMINISTERED STRONTIUM-CONTAINING COMPLEXES FOR TREATING PAIN, PRURITIS AND INFLAMMATION - A simplified explanation of the abstract==


This abstract first appeared for US patent application 20240041919 titled 'TOPICALLY ADMINISTERED STRONTIUM-CONTAINING COMPLEXES FOR TREATING PAIN, PRURITIS AND INFLAMMATION

==Simplified Explanation==

The patent application describes therapeutically-active compositions that combine strontium with additional molecules to increase the overall therapeutic potency of the combination. The combinations have two important functions: 

1. They enhance the ability of topically-applied strontium to inhibit acute sensory irritation (such as pruritus and pain), redness, swelling, and inflammation. They also reduce the chronic irritation that contributes to the development and maintenance of painful or pruritic neuropathic conditions.

2. They decrease the strontium-activated pathways that enhance the development and maintenance of pain, pruritus, and neuropathic conditions.

* The patent application describes compositions that combine strontium with other molecules to enhance its therapeutic effects.
* The combinations increase the ability of topically-applied strontium to inhibit acute sensory irritation, redness, swelling, and inflammation.
* The combinations also reduce chronic irritation associated with painful or pruritic neuropathic conditions.
* The compositions decrease the strontium-activated pathways that contribute to the development and maintenance of pain, pruritus, and neuropathic conditions.

Potential applications of this technology:

* Treatment of acute sensory irritation, redness, swelling, and inflammation.
* Management of chronic pain and pruritic neuropathic conditions.

Problems solved by this technology:

* Enhanced inhibition of acute sensory irritation and chronic irritation.
* Reduction of pain, pruritus, and neuropathic conditions.

Benefits of this technology:

* Increased therapeutic potency compared to separate constituents.
* Improved management of painful or pruritic neuropathic conditions.
* Reduction of inflammation and irritation.


==Original Abstract Submitted==

therapeutically-active compositions that combine strontium with at least one additional molecules that increase the overall therapeutic potency of the combination beyond the potency of any of the separate constituents. specifically, the combinations perform two important functions; (1) they increase the ability of topically-applied strontium to inhibit both acute sensory irritation (e.g., pruritus and pain), redness, swelling and inflammation (collectively defined for purposes of this description, “irritation”) and the chronic irritation that is characteristic of and contributes to the development and maintenance of painful or pruritic neuropathic conditions; and (2) they decrease the strontium activated pathways that are known to enhance the development and maintenance of pain, pruritis and neuropathic conditions.



[[Category:A61K33/00]]
[[Category:A61K9/00]]
[[Category:A61P29/00]]
[[Category:A61P17/18]]
[[Category:A61P17/00]]
[[Category:A61K33/24]]
[[Category:A61K31/265]]
[[Category:A61K31/198]]
[[Category:A61K31/192]]
[[Category:A61K31/05]]